Indian pharmaceutical company Hetero Drugs has received emergency use approval from the country's health authorities to make a generic version of Swiss healthcare company Roche Holding AG's (SWX:ROG.S) COVID-19 drug, tocilizumab, Reuters news agency reported on Monday.
Hetero expects to make tocilizumab available in India by the end of the month under the brand name Tocira.
It will reportedly be made by Hetero's unit at its Hyderabad facility.
Roche's arthritis drug, tocilizumab, cuts the risk of death among patients hospitalised with severe COVID-19 along with shortening the recovery time and reducing the need for mechanical ventilation.
Hikma Pharmaceuticals to acquire Custopharm from Water Street Healthcare Partners
Veklury Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Par Pharmaceutical starts shipping generic version of Pfizer's Chantix 0.5mg and 1mg tablets
Takeda's vaccine business grows as dengue and COVID-19 shots progress
Eisai and Fuji Yakuhin conclude of dotinurad development and distribution license agreement
Breckenridge Pharmaceutical launches Norepinephrine Bitartrate Injection, USP
Crescita Therapeutics and Stada Enter 15-Country Exclusive Licensing Agreement for Pliaglis
Cipla receives final US FDA approval for ANDA for Difluprednate Ophthalmic Emulsion 0.05%